KR900005975A - 카르복실산 유도체 - Google Patents
카르복실산 유도체 Download PDFInfo
- Publication number
- KR900005975A KR900005975A KR1019890015339A KR890015339A KR900005975A KR 900005975 A KR900005975 A KR 900005975A KR 1019890015339 A KR1019890015339 A KR 1019890015339A KR 890015339 A KR890015339 A KR 890015339A KR 900005975 A KR900005975 A KR 900005975A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- bismuth
- receptor antagonist
- salt
- acid
- Prior art date
Links
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title claims 5
- 150000003839 salts Chemical class 0.000 claims 12
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims 7
- -1 propyl citro Chemical compound 0.000 claims 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical group N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 2
- 229910052797 bismuth Inorganic materials 0.000 claims 2
- ANERHPOLUMFRDC-UHFFFAOYSA-K bismuth citrate Chemical compound [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ANERHPOLUMFRDC-UHFFFAOYSA-K 0.000 claims 2
- 229960001380 cimetidine Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 claims 2
- 229960004872 nizatidine Drugs 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- JEYKZWRXDALMNG-UHFFFAOYSA-N sufotidine Chemical compound CN1N=C(CS(C)(=O)=O)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 JEYKZWRXDALMNG-UHFFFAOYSA-N 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- 239000011975 tartaric acid Substances 0.000 claims 2
- 235000002906 tartaric acid Nutrition 0.000 claims 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- GIMNAEMRNXUAQP-UHFFFAOYSA-N 2-[4-(2-methyl-1h-imidazol-5-yl)-1,3-thiazol-2-yl]guanidine Chemical compound N1C(C)=NC=C1C1=CSC(N=C(N)N)=N1 GIMNAEMRNXUAQP-UHFFFAOYSA-N 0.000 claims 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- MAROFABTHUXYCY-UHFFFAOYSA-K [Bi+3].OC(CC(=O)[O-])(CC(=O)[O-])C(=O)[O-].C(C)C(=C(N)NC)[N+](=O)[O-] Chemical compound [Bi+3].OC(CC(=O)[O-])(CC(=O)[O-])C(=O)[O-].C(C)C(=C(N)NC)[N+](=O)[O-] MAROFABTHUXYCY-UHFFFAOYSA-K 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940040563 agaric acid Drugs 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims 1
- BTAYZXYEKGOVRG-UHFFFAOYSA-K bismuth;1-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Bi+3].[O-]C(=O)C(O)C(C([O-])=O)CC([O-])=O BTAYZXYEKGOVRG-UHFFFAOYSA-K 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229950001902 dimevamide Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZQHFZHPUZXNPMF-UHFFFAOYSA-N ebrotidine Chemical compound S1C(N=C(N)N)=NC(CSCCN=CNS(=O)(=O)C=2C=CC(Br)=CC=2)=C1 ZQHFZHPUZXNPMF-UHFFFAOYSA-N 0.000 claims 1
- 229950002377 ebrotidine Drugs 0.000 claims 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims 1
- 229960001596 famotidine Drugs 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229950008866 mifentidine Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 1
- GOZUADYOHPCXLE-UHFFFAOYSA-N n-[4-(1h-imidazol-5-yl)phenyl]-n'-propan-2-ylmethanimidamide Chemical compound C1=CC(NC=NC(C)C)=CC=C1C1=CN=CN1 GOZUADYOHPCXLE-UHFFFAOYSA-N 0.000 claims 1
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims 1
- 229960000620 ranitidine Drugs 0.000 claims 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical group [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229950002504 sufotidine Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229950003675 zaltidine Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/29—Antimony or bismuth compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (11)
- 염기성 히스타민 H2-수용체 길항제와, 비스무트와 카르복실산의 착물 사이에서 형성된 염 또는 염기성 H2-수용체 길항제가 라니티딘인 경우의 염을 제외한 이들 염의 용매화물.
- 제1항에 있어서, 카르복실산이 분자 중에 염기성 히스타민 H2-수용체 길항제와의 염 형성에 이용될 수 있는 카르복실기 이외에 적어도 3개의 관능기를 함유하는 염.
- 제1항에 있어서, 카르복실산이 시트르산, 타르타르산, 에틸렌디아민테트라아세트산, 프로필시트로산 또는 아가리신산인 염.
- 제1항에 있어서, 카르복실산이 시트르산 또는 타르타르산인 염.
- 제1 내지 4항중 어느 한 항에 있어서, 염기성 히스타민 H2-수용체 길항제가 이미다졸 유도체, 치환된 아미노알킬-벤젠, -푸란 또는 -티아졸 유도체, 구아니디노티아졸릴 유도체 또는 구아니디노 피라졸릴 유도체인 염.
- 제5항에 있어서, 염기성 히스타민 H2-수용체 길항제가 시메티딘, 서포티딘, 파모티딘, 록사티딘, 니페로티딘, 니자티딘, 미펜티딘, 잘티딘, 에브로티딘, 비스펜티딘, 1-메틸-5-[[3-(1-피페리디닐메틸)페녹시]프로필]아미노]-1H-1,2,4-트리아졸-3-메탄올, 3-아미노-4-[[3-(1-피페리디닐메틸)페녹시]프로필]아미노]-3-시클로부텐-1,2-디온 및 5-[3-(2,2,2-트리플루오로에틸)구아니디노]피라졸-1-일]발레르아미드중에서 선택된 어느 하나인 것을 특징으로 하는 염.
- 제5항에 있어서, 염기성 히스타민 H2-수용체 길항제가 시메티딘, 서포티딘, 파모티딘 및 니자티딘 중에서 선택된 어느 하나인 것을 특징으로 하는 염.
- N-시아노-N´-메틸-N″-[2-[[(5-메틸-1H-이미다졸-4-일)메틸]티오]에틸]구아니딘 2-히드록시-1,2,3-프로판트리카르복실레이트 비스무트(3+)착물 ; N-시아노- N´-메틸-N″-[2-[[(5-메틸-1H-이미다졸-4-일)메틸]티오]에틸]구아니딘[R-(R*R*)]-2,3-디히드록시부탄디오에이트 비스무트(3+)착물 ; 1-메틸-3-메틸설포닐메틸-N-[3-[3-(1-피페리디닐메틸)페녹시]프로필]-1H-1,2,4-트리아졸-5-아민 2-히드록시-1,2,3-프로판트리카르복실레이트 비스무트(3+)착물 ; 3-[[[2-[(아미노이미노메틸)아미노]-4-티아졸릴]메틸]티오]-N-(아미노설포닐)프로판이미드아미드 2-히드록시-1,2,3-프로판트리카르복실레이트 비스무트(3+)착물 ; N-[2-[[[2-[(디메틸아미노)메틸]-4-티아졸릴]메틸]티오]에틸-N´-메틸-2-니트로-1,1-에텐디아민 2-히드록시-1,2,3-프로판트리카르복실레이트 비스무트(3+)착물 및 이들의 용매화물.
- 제1항 내지 8항중 어느 한 항에 의한 염과 적어도 1종의 제약상 허용되는 담체 또는 부형제로 구성되는 제약조성물.
- 제1항 내지 8항중 어느 한 항에 의한 염의 활성치료제로서의 용도.
- 염기성 히스타민 H2-수용체 길항제를 적당한 용매중에서 비스무트 카르복실산 착물과 반응시키고, 생성된 혼합물에서 형성된 염을 분리시키는 것으로 되는 제1항 내지 8항중 어느 한 항에 의한 염의 제조방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB888825058A GB8825058D0 (en) | 1988-10-26 | 1988-10-26 | Chemical compounds |
| GB8825058.4 | 1988-10-26 | ||
| GB8914631.0 | 1989-06-26 | ||
| GB898914631A GB8914631D0 (en) | 1989-06-26 | 1989-06-26 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR900005975A true KR900005975A (ko) | 1990-05-07 |
| KR0148480B1 KR0148480B1 (ko) | 1998-11-02 |
Family
ID=26294554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019890015339A KR0148480B1 (ko) | 1988-10-26 | 1989-10-25 | 히스타민 h2-수용체 길항제의 염 및 용매화물 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5273984A (ko) |
| EP (1) | EP0367484B1 (ko) |
| JP (1) | JP2915021B2 (ko) |
| KR (1) | KR0148480B1 (ko) |
| AU (1) | AU641903B2 (ko) |
| CA (1) | CA2001436C (ko) |
| DE (1) | DE68913137T2 (ko) |
| ES (1) | ES2062031T3 (ko) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9009437D0 (en) * | 1990-04-26 | 1990-06-20 | Glaxo Group Ltd | Chemical compounds |
| US5843482A (en) * | 1990-07-20 | 1998-12-01 | Tillotts Pharma Ag | Products and processes for the treatment of the alimentary canal |
| GB9019875D0 (en) * | 1990-09-11 | 1990-10-24 | Glaxo Group Ltd | Pharmaceutical compositions |
| CA2052698A1 (en) * | 1990-10-11 | 1992-04-12 | Roger G. Berlin | Treatment of peptic ulcer |
| BG61302B1 (bg) * | 1993-09-30 | 1997-05-30 | Нихфи Ад | n-(3-(3-(1-пиперидинилметил)фенокси)пропил)хидроксиацетамид 1,2,3-пропентрикарбоксилат бисмут /3+/комплекс и метод за получаването му |
| US5834002A (en) | 1994-05-02 | 1998-11-10 | Josman Laboratories, Inc. | Chewing gum containing colloidal bismuth subcitrate |
| US6426085B1 (en) | 1994-05-02 | 2002-07-30 | Josman Laboratories Inc. | Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis |
| US6902738B2 (en) | 1994-05-02 | 2005-06-07 | Josman Laboratories, Inc. | Topical oral dosage forms containing bismuth compounds |
| GB9501560D0 (en) * | 1995-01-26 | 1995-03-15 | Nycomed Imaging As | Contrast agents |
| HUP9900428A2 (hu) * | 1995-01-26 | 1999-06-28 | Nycomed Imaging A/S | Bizmutvegyületek, ezeket tartalmazó diagnosztikai kontrasztanyag, ennek alkalmazása és ezt tartalmazó gyógyászati készítmény |
| US6379651B1 (en) | 1995-02-07 | 2002-04-30 | Josman Laboratories | Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases |
| US6372784B1 (en) | 1995-02-07 | 2002-04-16 | Josman Laboratories, Inc. | Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds |
| US6248551B1 (en) * | 1997-03-28 | 2001-06-19 | Institut Pasteur | Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides |
| CN1102585C (zh) * | 1999-04-28 | 2003-03-05 | 常州兰陵制药有限公司 | 雷尼替丁枸橼酸铋盐的制备方法 |
| US20030158118A1 (en) * | 2001-11-26 | 2003-08-21 | Weidner Morten Sloth | Combination of cimetidine and cysteine derivatives for treating cancer |
| US20050031706A1 (en) * | 2003-08-06 | 2005-02-10 | Pena Lorraine E. | Viscosity-stable compositions useful for treating gastrointestinal disorders |
| CN111592503B (zh) * | 2020-06-02 | 2021-07-16 | 青岛市食品药品检验研究院（青岛市药品不良反应监测中心、青岛市实验动物和动物实验中心） | 一种法莫替丁与苹果酸的共晶及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE135582T1 (de) * | 1985-06-13 | 1996-04-15 | Barry James Marshall | Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen |
| ATE81011T1 (de) * | 1987-03-09 | 1992-10-15 | Procter & Gamble | Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen. |
| IL85472A (en) * | 1987-03-09 | 1991-06-30 | Procter & Gamble | Pharmaceutical compositions for treating gastrointestinal disorders |
| CH679582A5 (ko) * | 1988-07-18 | 1992-03-13 | Glaxo Group Ltd |
-
1989
- 1989-10-24 AU AU43647/89A patent/AU641903B2/en not_active Ceased
- 1989-10-25 EP EP89310994A patent/EP0367484B1/en not_active Expired - Lifetime
- 1989-10-25 DE DE68913137T patent/DE68913137T2/de not_active Expired - Fee Related
- 1989-10-25 JP JP1278294A patent/JP2915021B2/ja not_active Expired - Lifetime
- 1989-10-25 CA CA002001436A patent/CA2001436C/en not_active Expired - Fee Related
- 1989-10-25 ES ES89310994T patent/ES2062031T3/es not_active Expired - Lifetime
- 1989-10-25 KR KR1019890015339A patent/KR0148480B1/ko not_active IP Right Cessation
- 1989-10-25 US US07/426,239 patent/US5273984A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2062031T3 (es) | 1994-12-16 |
| JPH02256623A (ja) | 1990-10-17 |
| KR0148480B1 (ko) | 1998-11-02 |
| EP0367484B1 (en) | 1994-02-16 |
| EP0367484A1 (en) | 1990-05-09 |
| DE68913137T2 (de) | 1994-05-26 |
| CA2001436C (en) | 2000-01-25 |
| AU4364789A (en) | 1990-05-03 |
| JP2915021B2 (ja) | 1999-07-05 |
| AU641903B2 (en) | 1993-10-07 |
| DE68913137D1 (de) | 1994-03-24 |
| US5273984A (en) | 1993-12-28 |
| CA2001436A1 (en) | 1990-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR900005975A (ko) | 카르복실산 유도체 | |
| KR910002826A (ko) | 푸란 유도체 | |
| GB1338169A (en) | Ureas thioureas and guanidines | |
| IE870889L (en) | Treatment of fungal infections | |
| Yamada et al. | Studies on a new 1, 5-benzothiazepine derivative (CRD-401) V. Antiarrhythmic actions | |
| RU97107457A (ru) | Производное азола | |
| IE36240L (en) | Sulphamides | |
| KR920005984A (ko) | 푸란 유도체를 함유하는 제약 조성물 | |
| EP0099121B1 (en) | Pharmaceutical compositions | |
| KR910021394A (ko) | 카르복실산 유도체 | |
| US4894375A (en) | Method of controlling mycotic infections and compositions therefor | |
| NO872781L (no) | 4-(aroylamino)piperidinbutanamid-derivater. | |
| WO2012047826A2 (en) | Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity | |
| CA2041175A1 (en) | Carboxylic acid derivatives | |
| US3297522A (en) | Method of using nu-cyclohexyl dihalo maleimide and nu-(4-methylphenyl) dihalo malemide fungicides | |
| US5312815A (en) | Fungicidal (+)-2-(2,4-difluorophenyl)-3-methyl-1-(1H-1,2,4-triazol-1-yl)3-(6-(1H-1,2,4-triazol-1-yl)pyridazin-3-ylthio) butan-2-ol | |
| JPH0233016B2 (ko) | ||
| HU187712B (en) | Fungicide compositions containing n-substituted 2-methyl-naphtyl-amide derivatives and process for producing n-substituted 2-methyl-naphtyl-amide derivatives | |
| MXPA02010177A (es) | Derivados de 1-(h-1, 2,4-triazol-1-il) butan-2- ol. | |
| Kane et al. | Coronary artery ligation in anaesthetized rats as a model for the assessment of antidysrhythmic activity; the effects of lignocaine, propranolol and ORG 6001 [proceedings] | |
| Hay | Antifungal drugs-an introduction | |
| JP2004518667A (ja) | 抗菌剤としてのアゾール化合物 | |
| KR970061897A (ko) | 신규한 세팔로스포린계 항생제 | |
| US2898342A (en) | 2(2'-propenylidene-amino)-1,3,4-thiadiazole-5-sulfonamide | |
| IE791420L (en) | Benzothiazole derivatives: anthelmintics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20010516 Year of fee payment: 4 |
|
| LAPS | Lapse due to unpaid annual fee |